Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Crescent Biopharma, Inc. (CBIO) had Income from Continuous Operations of $-105.20M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-105.20M |
|
-- |
|
-- |
|
$114.16M |
|
$-114.16M |
|
$0.12M |
|
$-103.20M |
|
$-103.20M |
|
$-105.20M |
|
|
Income from Continuous Operations |
$-105.20M |
$-105.20M |
|
$-105.20M |
|
$-103.32M |
|
$-114.11M |
|
10.41M |
|
10.41M |
|
$-2.61 |
|
$-2.61 |
|
| Balance Sheet Financials | |
$236.66M |
|
$0.85M |
|
$3.64M |
|
$240.29M |
|
$36.07M |
|
-- |
|
$1.21M |
|
$37.28M |
|
$199.01M |
|
$203.01M |
|
$203.01M |
|
27.56M |
|
| Cash Flow Statement Financials | |
$-71.53M |
|
$-72.92M |
|
$322.98M |
|
$34.77M |
|
$213.30M |
|
$178.53M |
|
$13.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-72.45M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-52.86% |
|
-51.82% |
|
-43.78% |
|
-51.82% |
|
$7.37 |
|
$-6.96 |
|
$-6.87 |
|